ABSTRACT

Background: Schizophrenia remains a major public health concern globally due to its chronic, recurrent nature and the substantial burden it places on patients, caregivers, and health systems Schizophrenia is a chronic psychiatric disorder characterized by a relapsing-remitting course. This problem is even more pronounced in low-resource settings such as Nigeria, where socioeconomic instability, insecurity, inadequate access to mental health services, high treatment costs, cultural misconceptions, and caregiver burden significantly heighten relapse risk. In Northern Nigeria, high rates of readmission pose significant challenges to functional recovery and healthcare resources. This study investigated the factors contributing to relapse among patients with schizophrenia at Federal Medical Center (FMC) Gusau.
Methods: A cross-sectional descriptive design was employed with a sample of 154 patients at the FMC Gusau, psychiatric unit. Data were collected using a structured questionnaire and medical record reviews. Logistic regression was used to identify independent predictors of relapse, with significance set at p < 0.05.
Results: The majority of respondents were aged 26–35 years (35.7%) and male (63.6%). Significant patient-related factors included medication non-adherence (68.2%) and stopping medication upon symptom improvement (64.3%). Regression analysis identified the strongest predictors of relapse as missing medications (AOR = 3.85), high medication cost (AOR = 3.45), and lack of family supervision (AOR = 3.12).
Conclusion: Relapse in this setting is primarily driven by economic barriers and failures in the community support system. Interventions should prioritize the affordability of antipsychotics and structured family psychoeducation to reduce the revolving door of psychiatric readmission.

kEYWORDS

Schizophrenia, Relapse, Medication Adherence, Family Support, Zamfara State.

REFERENCES

1) Balarabe F, Gommaa HIM, Abdellatif SA, Mohammed A. Prevalence and Predictors of Relapse among Patients with Schizophrenia at Psychiatric Healthcare Institutions in North-Western Nigeria. Bayero Journal of Nursing and Health Care. 2022;4(1):939-948.
2) Behera, S., et al. (2023). Medication adherence and its impact on health care costs among chronic psychiatric patients. The Research Review, 13(1). (Source for the 72.1% medication discontinuation rate among 11,797 patients).
3) Beyene, M. G., Teferra, S., & Fenta, T. G. (2025). Non–adherence and predictors in patients with schizophrenia on second generation antipsychotics at Amanuel Mental Specialized Hospital, Ethiopia. PLOS ONE, 20(3), e0314403. https://doi.org/10.1371/journal.pone.0314403
4) Birhan et al. Relapse and associated factors among psychiatric patients in Africa: a systematic review and meta-analysis. BMC Psychiatry. 2025;25:333.
5) Kameg, B., & Champion, C. (2022). Atypical antipsychotics: Managing adverse effects. Perspectives in Psychiatric Care, 58(2), 691–695. https://doi.org/10.1111/ppc.12837
6) Kane, J. M., Agid, O., Baldwin, D. S., Howes, O., Goldberg, J. F., & Correll, C. U. (2021). Guidelines for the clinical use of long-acting injectable antipsychotics. The Journal of Clinical Psychiatry, 82(4), 20m13624.
7) King HC, King JMK. Financing Mental Health in Nigeria (2021–2025): Budgetary Trends, Comparative Evidence, and Reform Pathways. The Nigerian Health Journal. 2026;26(1).
8) Lin, D., Thompson-Leduc, P., Ghelerter, I., Guérin, A., Ivorra, J. L., Kane, J. M., &… (2021). Adherence to oral versus long-acting injectable antipsychotics: A retrospective observational study. Journal of Clinical Psychiatry.
9) Mi WF, Chen XM, Fan TT, et al. Identifying modifiable risk factors for relapse in patients with schizophrenia in China. Frontiers in Psychiatry. 2020;11:574763.
10) Minwuyelet, F., Mulugeta, H., Tsegaye, D., Lake, B., Getie, A., Tsegaye, B., & Mullu, G. (2022). Quality of life and associated factors among patients with epilepsy at specialized hospitals, Northwest Ethiopia. PLOS ONE, 17(1), e0262814. https://doi.org/10.1371/journal.pone.0262814
11) Olfson, M., et al. (2020). Trends in the prescription of antipsychotic and antidepressant drugs across clinical populations. Journal of Clinical Psychiatry, 81(3).
12) Ran, M. S., Xiang, M. Z., Chan, C. L., Leff, J., Simpson, P., Huang, M. S., Shan, Y. H., & Li, S. G. (2015). The effectiveness of psychoeducational family intervention for patients with schizophrenia in a 14-year follow-up study in a Chinese rural area. Psychological Medicine, 45(6), 1197–1207. https://doi.org/10.1017/S0033291715000197
13) World Health Organization. Schizophrenia Fact Sheet. Geneva: WHO; 2025.

Cite this article

Michael, O. S., Evangeline, A. C., Juliet, N. N., Malami, K., Jega, S. M., Abu, A. B. D., & Abubakar, S. A. (2026). Determinants of Psychotic Relapse in Patients with Schizophrenia: A Cross-Sectional Study at the Federal Medical Center, Gusau, Zamfara State. INTERNATIONAL JOURNAL OF HEALTH & MEDICAL RESEARCH, 5(5), 480-484. https://doi.org/10.58806/ijhmr.2026.v5i5n20